Welcome to our dedicated page for Meihua International Medical Technologies Co., Ltd. SEC filings (Ticker: MHUAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Meihua International Medical Technologies Co., Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Meihua International Medical Technologies Co., Ltd.'s regulatory disclosures and financial reporting.
Meihua International Medical Technologies Co., Ltd. director Jia Wenzhang reported an existing option position in a Form 3/A amendment. The filing shows a stock option with an exercise price of $530.0000 per share, linked to 19.0000 shares of common stock and expiring on June 27, 2032. Following this report, the option position covers a total of 19.0000 underlying common shares held directly.
Meihua International Medical Technologies Co., Ltd. reported that Jia Wenzhang, serving as an Independent Director, filed an initial Form 3 statement of beneficial ownership. The filing shows no reported transactions and no derivative positions, reflecting only the person’s status as a reporting insider.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for reporting person Colin Anna, who serves as an Independent Director of the company. This filing is an initial statement of beneficial ownership and does not report any stock purchases, sales, option exercises, or other transactions.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for officer Wang Ailiang, who is listed as Chairwoman. The filing reports no insider transactions, no current share holdings, and no outstanding derivative positions for her at this time.
Meihua International Medical Technologies Co., Ltd. CEO Lee Leyi has filed an initial insider ownership report on Form 3. The data provided shows no reported transactions or derivative positions, and no current holding entries are listed for this reporting person.
Meihua International Medical Technologies Co., Ltd. filed an initial Form 3 for its CFO, Liao Shilong, reporting his beneficial ownership status in the company’s securities. The filing shows no reported transactions, no reported share acquisitions or dispositions, and no listed derivative positions at the time of this statement.
Meihua International Medical Technologies reports that Nasdaq has moved forward with delisting its securities. Nasdaq staff initially determined to delist the shares in December 2025, and trading of the Company’s class A ordinary shares was suspended and moved to the OTC Marketplace under the symbol “MHUAF” on December 9, 2025.
The Company appealed and attended a hearing before a Nasdaq Hearings Panel on January 27, 2026, but on February 24, 2026 the Panel denied the request to reinstate trading and determined to delist the securities. On March 2, 2026, the Company requested further review of the Panel’s delisting decision by the Nasdaq Listing and Hearing Review Council.
Meihua International Medical Technologies has modified earlier lock-up restrictions on investors in its October 8 and December 5, 2025 private placements. On January 29, 2026, the company entered leak-out agreements that waive the prior 12‑month lock-up on these securities.
Instead of a full resale ban, each purchaser now agrees that, during the leak-out period, sales on any trading day will not exceed 15% of the average daily trading volume over the prior ten trading days, while the ordinary shares trade on specified U.S. exchanges. The leak-out terms apply once the securities are registered for resale or become sellable under Rule 144.
Meihua International Medical Technologies Co., Ltd. reports that investors in its recent private placements have agreed to lock-up restrictions on their shares. The company previously completed an October offering of 40,000,000 ordinary shares (or 400,000 Class A ordinary shares on a post reverse-split and post re-designation basis) for gross proceeds of $15.2 million, and a December offering of up to 120,000 Class A ordinary shares for gross proceeds of $1.32 million. On January 22, 2026, all purchasers from both offerings entered into a lock-up agreement, committing for 12 months after each closing not to sell, pledge, or otherwise dispose of their Meihua securities or seek registration of those securities without the company’s prior written consent.